Accessibility Menu
Orchestra BioMed logo

Orchestra BioMed(NASDAQ) OBIO

Market Cap$238.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-65%
5 Year-60%
1 Year+30%
1 Month-7%
$3.97
-0.63%
-0.03Today
After hours$3.98+$0.01 (+0.38%)
Orchestra BioMed last closing stock price
MetricPriceDate
Last closeUSD 3.982026-07-31
Orchestra BioMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.42%USD 3.742026-07-24
1 month-7.44%USD 4.302026-07-01
3 month+0.25%USD 3.972026-05-01
Year to date-4.1%USD 4.152025-12-31
1 year+30.07%USD 3.062025-07-31
3 year-27.64%USD 5.502023-08-01
5 year-59.84%USD 9.912021-07-30
Since inception-65.09%USD 11.402020-08-04

Orchestra BioMed Financials at a Glance

Market Cap

$238.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$32.72M

Net Income (TTM)

-$54.64M

EPS (TTM)

-$1.13

P/E Ratio

-3.53

Dividend

$0.00

Beta (Volatility)

0.93 (Low)

Price

$3.97

Volume

153,852

Open

$3.98

Previous Close

$3.98

Daily Range

$3.84 - $4.06

52-Week Range

$2.20 - $5.42

Estimated Earnings Date

Aug 11, 2026

OBIO News

hearthealth

Why Shares of Orchestra BioMed Jumped Tuesday

James HalleySep 19, 2023
Nurse tending patient in intensive care (1)

Why Shares of Orchestra BioMed Holdings Jumped Wednesday

James HalleyJun 28, 2023
nurse and doctors in masks discussing chart

Why Shares of Orchestra BioMed Jumped This Week

James HalleyMar 24, 2023

OBIO: Motley Fool Moneyball Superscore

53

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Orchestra BioMed

Orchestra BioMed makes medical tools for heart and artery health. It works with big companies to bring products to patients. These tools treat high blood pressure and blocked arteries.

What Orchestra BioMed Makes

  • AVIM Therapy: Heart stimulation treatment for high blood pressure; used in patients who already require a pacemaker device.
  • Virtue SAB: Medicine-delivery balloon that treats blocked arteries without the need for a permanent metal implant or stent.
  • FreeHold Retractors: Hand-held surgical tools that help doctors see better during operations with small incisions; generated 100% of revenue in Q1 2026.

Strategic Deals and Expansions

  • Partnered with Medtronic in 2022 to develop and sell heart stimulation therapies globally.
  • Secured a $35 million funding agreement with Ligand Pharmaceuticals in July 2025.
  • Regained full control of the Virtue SAB program from Terumo Corporation in October 2025.
  • Expanded the Medtronic deal in 2025 to include work on wireless heart devices.

A Different Way to Innovate

The company uses a partnership model to reduce the financial risks of developing new medical devices. This strategy relies on the global sales teams of larger partners to distribute finished products.

Recent Performance Metrics

  • Total revenue was $110,000 in Q1 2026, down 87.3% from $868,000 in Q1 2025.
  • Net loss was $20.7 million in Q1 2026, which worsened 10.3% from the same period in 2025.
  • Operating cash flow reached negative $22.2 million in Q1 2026, a 33.4% deepening from Q1 2025.
  • Research and development costs rose to $15.8 million in Q1 2026 from $13.5 million in Q1 2025.

The Big Picture

Orchestra BioMed focuses on technical heart health innovation through strategic risk-sharing with industry leaders. Its evolution into a public company is marked by high research spending and major corporate alliances.

AI Generated • May 19, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

86

CEO

David P. Hochman

Website

www.orchestrabiomed.com

Headquarters

New Hope, PA 18938, US

OBIO Financials

Key Financial Metrics (TTM)

Gross Margin

99.27%

Operating Margin

-167.96%

Net Income Margin

-166.96%

Return on Equity

-137.99%

Return on Capital

-65.30%

Return on Assets

-54.28%

Earnings Yield

-28.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$238.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

59.88M

Volume

153.85K

Avg. Volume

327.02K

Financials (TTM)

Gross Profit

$32.49M

Operating Income

-$54.96M

EBITDA

-$52.72M

Operating Cash Flow

-$54.52M

Capital Expenditure

-$561.00K

Free Cash Flow

-$55.08M

Cash & ST Invst.

$94.40M

Total Debt

$33.64M

Orchestra BioMed Performance Analysis

Orchestra BioMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,533,000N/A
20232023-12-31USD 2,760,000-21.9%
20242024-12-31USD 2,638,000-4.4%
20252025-12-31USD 33,482,0001169.2%
Orchestra BioMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-3.7%
Q32025-09-303.0%
Q42025-12-313490.8%
Q12026-03-31-99.6%
Orchestra BioMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.2412020.0%
20232023-12-31USD -1.48-34.1%
20242024-12-31USD -1.6612.1%
20252025-12-31USD -1.11-33.1%
Orchestra BioMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-2.0%
Q32025-09-30-8.0%
Q42025-12-31129.6%
Q12026-03-31-437.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$110.00K

-87.3%

Gross Profit

$18.00K

-97.8%

Gross Margin

16.36%

N/A

Market Cap

$238.33MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.77M

N/A

Employees

86

N/A

Net Income

-$20.69M

-10.3%

EBITDA

-$19.78M

-5.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$94.40M

+89.2%

Total Debt

$33.64M

+104.5%

Accounts Receivable

$84.00K

-5.6%

Inventory

$277.00K

+105.2%

Long Term Debt

$32.85M

+107.2%

Short Term Debt

$785.00K

+33.1%

Return on Assets

-54.28%

N/A

Return on Invested Capital

-63.20%

N/A

Free Cash Flow

-$22.35M

-33.6%

Operating Cash Flow

-$22.17M

-33.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IVAInventiva S.A.
$4.48-3.03%
TARAProtara Therapeutics, Inc.
$3.92-2.73%
PRLDPrelude Therapeutics Incorporated
$4.60-8.91%
EPRXEupraxia Pharmaceuticals Inc.
$6.40-2.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About OBIO

What is the current price of Orchestra BioMed?

Orchestra BioMed is trading at $3.98 per share.

What is the 52-week range for Orchestra BioMed?

Over the past 52 weeks, Orchestra BioMed has traded between $2.20 and $5.42.

How much debt does Orchestra BioMed have?

As of the most recent reporting period, Orchestra BioMed reported total debt of $33.64M.

How much cash does Orchestra BioMed have on hand?

Orchestra BioMed reported $28.37M in cash and cash equivalents in its most recent financial results.

What is Orchestra BioMed’s dividend yield?

Orchestra BioMed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services